From validation to public health impact: implementing equitable AI-enabled diabetic retinopathy screening.
- 1Department of Ophthalmology, People's Hospital of Leshan, Leshan, Sichuan, China.
Abstract
Diabetic retinopathy (DR) remains a preventable cause of vision loss as diabetes prevalence rises worldwide. Artificial intelligence (AI)-enabled retinal screening has progressed from retrospective validation to prospective and real-world deployment, with recent reviews showing high diagnostic performance across fundus photography, smartphone-based systems, and autonomous platforms. Yet diagnostic accuracy alone does not ensure public health benefit. Population impact can be lost when eligible people are not reached, images are ungradable, results are delayed, referrals are incomplete, treatment capacity is insufficient, or disadvantaged groups face financial, geographic, or digital barriers. Unlike reviews centered mainly on diagnostic accuracy or economic performance, this Mini Review reframes AI-enabled DR screening as a population-health intervention spanning detection through completion of effective eye care. We synthesize evidence on diagnostic validity, implementation, economics, referral completion, care cascades, patient-centered outcomes, equity, and governance. We argue that effectiveness and cost-effectiveness are properties of the complete screening-to-treatment pathway, not the algorithm alone, and propose a four-domain framework encompassing technical validity, service integration, population impact, and equity and sustainability. Future research should prioritize comparative implementation studies and outcome sets that capture screening reach, gradability, referral completion, treatment initiation, time to treatment, avoidable vision loss, vision-related quality of life, acceptability, costs, and subgroup equity. The policy question is no longer whether AI can detect DR, but whether health systems can translate automated detection into equitable completion of effective eye care at scale.
Related
- Performance Assessment of an Artificial Intelligence System Used for Case Detection in a Large Community-based Diabetic Retinopathy Screening Program: A Retrospective Diagnostic Accuracy Validation Study.
- ACCESS2 study: the potential for autonomous AI to mitigate disparities in diabetic retinopathy screening in youth
- Artificial intelligence-supported diabetic retinopathy screening in Tanzania: a randomised controlled trial
- Clinical setting-dependent diagnostic accuracy of artificial intelligence and store-and-forward diabetic retinopathy screening: a systematic review and meta-analysis
- Systematic validation of zucker diabetic-sprague dawley male rats as a model for type 2 diabetes-associated diabetic retinopathy
BibTeX
@article{chen2026from,
title = {{From validation to public health impact: implementing equitable AI-enabled diabetic retinopathy screening.}},
author = {Jing Chen and Bin Chen},
journal = {Frontiers in public health},
year = {2026},
month = oct,
doi = {10.3389/fpubh.2026.1976572},
url = {https://europepmc.org/article/MED/42898801},
note = {CC BY},
}
RIS
TY - JOUR
TI - From validation to public health impact: implementing equitable AI-enabled diabetic retinopathy screening.
AU - Jing Chen
AU - Bin Chen
PY - 2026
DA - 2026/10/05
JO - Frontiers in public health
DO - 10.3389/fpubh.2026.1976572
UR - https://europepmc.org/article/MED/42898801
AB - Diabetic retinopathy (DR) remains a preventable cause of vision loss as diabetes prevalence rises worldwide. Artificial intelligence (AI)-enabled retinal screening has progressed from retrospective validation to prospective and real-world deployment, with recent reviews showing high diagnostic performance across fundus photography, smartphone-based systems, and autonomous platforms. Yet diagnostic accuracy alone does not ensure public health benefit. Population impact can be lost when eligible people are not reached, images are ungradable, results are delayed, referrals are incomplete, treatment capacity is insufficient, or disadvantaged groups face financial, geographic, or digital barriers. Unlike reviews centered mainly on diagnostic accuracy or economic performance, this Mini Review reframes AI-enabled DR screening as a population-health intervention spanning detection through completion of effective eye care. We synthesize evidence on diagnostic validity, implementation, economics, referral completion, care cascades, patient-centered outcomes, equity, and governance. We argue that effectiveness and cost-effectiveness are properties of the complete screening-to-treatment pathway, not the algorithm alone, and propose a four-domain framework encompassing technical validity, service integration, population impact, and equity and sustainability. Future research should prioritize comparative implementation studies and outcome sets that capture screening reach, gradability, referral completion, treatment initiation, time to treatment, avoidable vision loss, vision-related quality of life, acceptability, costs, and subgroup equity. The policy question is no longer whether AI can detect DR, but whether health systems can translate automated detection into equitable completion of effective eye care at scale.
SN - 2296-2565
ER -